SOURCES SOUGHT
66 -- Detection Reagents
- Notice Date
- 4/16/2015
- Notice Type
- Sources Sought
- NAICS
- 325414
— Biological Product (except Diagnostic) Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse, Station Support/Simplified Acquisitions, 31 Center Drive, Room 1B59, Bethesda, Maryland, 20892
- ZIP Code
- 20892
- Solicitation Number
- HHS-NIH-NIDA-SSSA-SBSS-15-224
- Archive Date
- 5/15/2015
- Point of Contact
- Andrea McGee, Phone: 3014358718
- E-Mail Address
-
amcgee@nida.nih.gov
(amcgee@nida.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- SOLICITATION NUMBER: HHS-NIH-NIDA-SSSA-SBSS224 TITLE: Detection Reagents INTRODUCTION This is a Small Business Sources Sought notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding: (1) the availability and capability of qualified small business sources; (2) whether they are small businesses; HUBZone small businesses; service-disabled, veteran-owned small businesses; 8(a) small businesses; veteran-owned small businesses; woman-owned small businesses; or small disadvantaged businesses; and (3) their size classification relative to the North American Industry Classification System (NAICS) code for the proposed acquisition. Your responses to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. An organization that is not considered a small business under the applicable NAICS code should not submit a response to this notice. This notice is issued to help determine the availability of qualified companies technically capable of meeting the Government requirement and to determine the method of acquisition. It is not to be construed as a commitment by the Government to issue a solicitation or ultimately award a contract. Responses will not be considered as proposals or quotes. No award will be made as a result of this notice. The Government will NOT be responsible for any costs incurred by the respondents to this notice. This notice is strictly for research and information purposes only. Purpose and Objectives: The purpose of this requirement is to acquire the purchase of detection reagents from Promega Corporation: ONE-Glo TM Luciferase Assay System, CellTiter-Fluor TM Cell Viability Assay and CellTiter-Glo ® Cell Viability Assay. Project Background: The Tox21 group of National Center for Advancing Translational Sciences (NCATS), Division of Preclinical Innovation (DPI) will screen compounds from Tox21 10K library with an assays like CAR (two modes: agonist and antagonist), SHH Gli3 (two modes) etc. which are some of current ongoing projects for a luciferase based methods. All the luciferase based methods are multiplexed with a cytotoxicity assay by using CellTiter-Fluor TM Cell Viability Assay. The ONE-Glo TM Luciferase Assay System is required for detection of luciferase based assays and the other two assay systems are required to run a parallel Cytotoxicity assays to each and every approved Tox21 assays. Project Requirements: This request (ONE-Glo and CellTiter-Fluor) will be used for screening against Tox21 compounds for the following cell lines: 1. hCAR (for two modes: agonist and antagonist mode) 2. AR-MDA (for one mode: antagonist mode), and 3. CMV-Luc (for one mode: agonist mode). All these cells contain a luciferase reporter gene (Luc) under the control of a target (gene) response element and the detection of stimulation or inhibition of the target genes is by measuring the firefly luciferase reporter gene expression in cells in terms of relative luminescence units. For the hCAR assay, luciferase activity is detected in a double-stable hCAR1-CYP2B6-HepG2 cell line. HepG2 cells were transfected with a pEF6/V5- hCAR1 expression plasmid and a pGL4.17[luc2/Neo]-CYP2B6-2.2kb construct containing both the PBREM and XREM. For AR_MDA, Luciferase activity is detected in stable transformed MDA- MB-453 cells, with MMTV.luciferase.neo reporter gene construct. For CMV-Luc, Luciferase activity is detected by measuring luciferse 2 reporter gene expression in stable transformed Hek293 cells with CMV promoter. So, all these screenings (hCAR, AR-MDA and CMV-Luc) require ONE-Glo TM Luciferase assay system and CellTiter-Fluor TM Cell Viability assay systems. ONE-Glo TM Luciferase assay system detects the expression of luciferase reporter gene, whereas CellTiter-Fluor TM Cell Viability assay systems is used for measuring the relative number of viable cells based on measurement of protease activity within live cells. This assay system is always been used in conjunction (or by multiplexing) with the ONE-Glo assay. CellTiter-Glo® cell Viability assay is used for measuring the cytotoxicity of the projects which are mainly aimed to detect the toxicity of the Tox21 chemicals against the target of interest. But in most of the Tox21 assays, this reagent is also used in conjunction with the fluorescence based assays (such as HRE-bla ME-180) for measuring the number of viable cells in cells based on the quantitation of the ATP present. Anticipated period of performance: 1 to 3 days ARO. These reagents are required after a couple of months which we anticipate by June 1, 2015. CAPABILITY STATEMENT Contractors that believe they possess the ability to provide the required equipment should submit documentation of their ability to meet each of the project requirements to the Contract Specialist. Contractors should also provide their Company Name, DUNS number, Physical Address, and Point of Contact Information. Interested organizations are required to identify their type of business, applicable North American Industry Classification System Code, and size standards in accordance with the Small Business Administration. The government requests that no proprietary or confidential business data be submitted in a response to this notice. However, responses that indicate the information therein is proprietary will be properly safeguarded for Government use only. Capability statements must include the name and telephone number of a point of contact having authority and knowledge to discuss responses with Government representatives. Capability statements in response to this market survey that do not provide sufficient information for evaluation will be considered non-responsive. When submitting this information, please reference the solicitation notice number. All capability statements sent in response to this Small Business Sources Sought Notice must be submitted electronically (via email) to Andrea McGee, Contract Specialist @ andrea.mcgee@nih.gov. on or before April 30, 4:00 p.m. eastern time. The response must in in Microsoft Word, Adobe PDF format using 11-point or 12-point font, 8-1/2" x 11" paper size, with 1" top, bottom, left and right margins, and with single or double spacing. Disclaimer and Important Notes. This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization's qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a pre-solicitation synopsis and solicitation may be published in Federal Business Opportunities. However, responses to this notice will not be considered adequate responses to a solicitation. Confidentiality. No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s).
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NIDA-2/HHS-NIH-NIDA-SSSA-SBSS-15-224/listing.html)
- Place of Performance
- Address: 9800 Medical Center Drive, Rockville, Maryland, 20850, United States
- Zip Code: 20850
- Zip Code: 20850
- Record
- SN03702506-W 20150418/150416235353-bac059fe2314f2c957cf853ad596c02a (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |